sub:assertion {
  d:DB06695 v:identifier "DB06695" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB06695" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB06695> ;
    dv:drugbank-id "DB06695" ;
    dv:x-ahfs <http://bio2rdf.org/ahfs:20:12.04.12> ;
    dv:x-atc <http://bio2rdf.org/atc:B01AE07> ;
    dv:x-cas <http://bio2rdf.org/cas:211915-06-9> ;
    dv:x-chebi <http://bio2rdf.org/chebi:70746> ;
    dv:x-chemspider <http://bio2rdf.org/chemspider:4948999> ;
    dv:x-kegg <http://bio2rdf.org/kegg:D07144> ;
    dv:x-ndc <http://bio2rdf.org/ndc:21695-899-60> ;
    dv:x-pharmgkb <http://bio2rdf.org/pharmgkb:PA165958369> ;
    dv:x-pubchemcompound <http://bio2rdf.org/pubchem.compound:6445226> ;
    dv:x-pubchemsubstance <http://bio2rdf.org/pubchem.substance:99443249> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Dabigatran> ;
    dct:description "Dabigatran etexilate is an oral prodrug that is metabolized by a serum esterase to dabigatran. It is a synthetic, competitive and reversible direct thrombin inhibitor. Inhibition of thrombin disrupts the coagulation cascade and inhibits the formation of clots. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients who have undergone total hip or knee replacement surgery, or to prevent stroke and systemic embolism in patients with atrial fibrillation, in whom anticoagulation therapy is indicated. In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary. FDA approved on October 19, 2010."@en ;
    dct:identifier "drugbank:DB06695" ;
    dct:title "Dabigatran etexilate"@en ;
    a dv:Drug ;
    rdfs:label "Dabigatran etexilate [drugbank:DB06695]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB06695> , <http://www.drugs.com/cdi/dabigatran.html> , <http://www.pdrhealth.com/drugs/pradaxa> , <http://www.rxlist.com/pradaxa-drug.htm> .
}